Themis Medicare Q4 FY26: Profitability returns as the mix shifts toward APIs and hospitals

Consolidated net revenue in Q4 FY26 was 76.53 crore, compared with 71.70 crore in Q4 FY25.

Q4 FY26 EBITDA was 3.76 crore versus -5.78 crore in Q4 FY25, and Q4 FY26 PAT was 8.89 crore versus -9.66 crore.

FY26 net revenue was 342.24 crore and PAT was 1.14 crore, compared with 405.51 crore revenue and 29.83 crore PAT in FY25.

For FY26, the presentation states Hospital business contributed 50%, Trade business 26%, and API, Co. Mkt and Others 24%.

The company targets Phase I expansion into CIS, Latin America and GCC in 0 to 3 years, and Phase II entry into regulated markets EU and USA in 3 to 5 years.

As of 31 Mar 2026, shareholders funds were 398.58 crore, short-term borrowings were 78.23 crore, long-term borrowings were 21.86 crore and trade receivables were 178.12 crore.

The presentation shows FY25-26 R&D spend of 11 crore and management stated R&D investments remained around 3% of revenue.